CH418528A - Verfahren zur Herstellung einer neuen als Arzneimittel zur oralen Verabreichung geeigneten amprotropinhaltigen Zubereitung - Google Patents
Verfahren zur Herstellung einer neuen als Arzneimittel zur oralen Verabreichung geeigneten amprotropinhaltigen ZubereitungInfo
- Publication number
- CH418528A CH418528A CH709962A CH709962A CH418528A CH 418528 A CH418528 A CH 418528A CH 709962 A CH709962 A CH 709962A CH 709962 A CH709962 A CH 709962A CH 418528 A CH418528 A CH 418528A
- Authority
- CH
- Switzerland
- Prior art keywords
- amprotropin
- medicament
- new
- production
- oral administration
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US117505A US3138525A (en) | 1961-06-16 | 1961-06-16 | Castor wax-amprotropine-resin compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH418528A true CH418528A (de) | 1966-08-15 |
Family
ID=22373300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH709962A CH418528A (de) | 1961-06-16 | 1962-06-13 | Verfahren zur Herstellung einer neuen als Arzneimittel zur oralen Verabreichung geeigneten amprotropinhaltigen Zubereitung |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US3138525A (de) |
| CH (1) | CH418528A (de) |
| GB (1) | GB935639A (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1792233B1 (de) * | 1967-08-12 | 1971-10-07 | Geigy Ag J R | Verfahren zur Stabilisierung eines oralen,fluessigen Arzneimittels auf der Basis von Imipramin und einem Ionenaustauscherharz |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3499960A (en) * | 1965-01-25 | 1970-03-10 | Merck & Co Inc | Palatable coated particles of an anion exchange resin |
| US4221778A (en) * | 1979-01-08 | 1980-09-09 | Pennwalt Corporation | Prolonged release pharmaceutical preparations |
| US4762709A (en) * | 1983-09-16 | 1988-08-09 | Pennwalt Corporation | Liquid prolonged release pharmaceutical formulations containing ionic constituents |
| AU565487B2 (en) * | 1983-09-16 | 1987-09-17 | Fisons Corporation | Liquid prolonged release pharmaceutical formulations containing ionic constituents |
| FR2576213B1 (fr) * | 1985-01-21 | 1989-02-24 | Cortial | Nouveau procede d'obtention de formes pharmaceutiques a liberation prolongee |
| ES8604955A1 (es) * | 1985-11-08 | 1986-03-16 | Covex Sa | Procedimiento para la preparacion de resinatos de la (-) eburnamenina-14-(15h)-ona |
| US4894239A (en) * | 1987-06-02 | 1990-01-16 | Takeda Chemical Industries, Ltd. | Sustained-release preparation and production thereof |
| US5219563A (en) * | 1988-05-11 | 1993-06-15 | Glaxo Group Limited | Drug adsorbates |
| IL90245A (en) * | 1988-05-11 | 1994-04-12 | Glaxo Group Ltd | Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it |
| US4996047A (en) * | 1988-11-02 | 1991-02-26 | Richardson-Vicks, Inc. | Sustained release drug-resin complexes |
| CA2002492A1 (en) * | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
| US5186930A (en) * | 1988-11-14 | 1993-02-16 | Schering Corporation | Sustained release oral suspensions |
| ES2202302T3 (es) * | 1991-05-28 | 2004-04-01 | Mcneil-Ppc, Inc. | Composicion masticable que libera un farmaco. |
| CA2309597A1 (en) | 1997-11-10 | 1999-05-20 | Hiroshi Sorimachi | Sustainedly releasing agents for medicines and sustainedly released medicinal compositions containing the same |
| EP1183014B1 (de) | 1999-06-14 | 2003-10-08 | Cosmo S.p.A. | Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe |
| US8895064B2 (en) | 1999-06-14 | 2014-11-25 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
| CN101253179B (zh) * | 2005-09-21 | 2010-12-29 | 株式会社钟根堂 | S-氯吡格雷的树脂酸盐复合物及其制备方法 |
| CN102488652B (zh) | 2006-03-16 | 2014-06-18 | 特瑞斯制药股份有限公司 | 含有药物-离子交换树脂复合物的经修饰释放的制剂 |
| WO2008042218A1 (en) * | 2006-10-03 | 2008-04-10 | Tris Pharma, Inc. | Formulations containing an ionic mineral-ion exchange resin complex and uses thereof |
| US20130230587A1 (en) | 2010-11-10 | 2013-09-05 | Rubicon Research Private Limited | Sustained release compositions |
| HRP20151321T1 (hr) | 2011-01-20 | 2016-01-29 | Bionevia Pharmaceuticals Inc. | Epalrestat ili njegov derivat u oblicima s prilagođenim otpuštanjem te postupci uporabe istih |
| US10154964B2 (en) | 2011-09-07 | 2018-12-18 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
| CA2880456A1 (en) | 2012-08-15 | 2014-02-20 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
| WO2016001937A2 (en) * | 2014-06-30 | 2016-01-07 | Rubicon Research Private Limited | Modified release pharmaceutical preparations |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| WO2019126216A1 (en) | 2017-12-18 | 2019-06-27 | Tris Phama, Inc. | Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
| EP3737353A1 (de) | 2017-12-18 | 2020-11-18 | Tris Pharma, Inc. | Pharmazeutische ghb-zusammensetzungen mit einem system zur formung von schwimmenden interpenetrierenden polymernetzwerken |
| US11337919B2 (en) | 2017-12-18 | 2022-05-24 | Tris Pharma, Inc. | Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release |
| WO2019126214A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release |
| WO2024163966A1 (en) | 2023-02-03 | 2024-08-08 | Tris Pharma, Inc. | Low sodium oxybate once nightly composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2805977A (en) * | 1955-01-04 | 1957-09-10 | Smith Kline French Lab | Sustained release pharmaceutical preparation |
| US2990332A (en) * | 1958-04-02 | 1961-06-27 | Wallace & Tiernan Inc | Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith |
-
1961
- 1961-06-16 US US117505A patent/US3138525A/en not_active Expired - Lifetime
-
1962
- 1962-06-07 GB GB21984/62A patent/GB935639A/en not_active Expired
- 1962-06-13 CH CH709962A patent/CH418528A/de unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1792233B1 (de) * | 1967-08-12 | 1971-10-07 | Geigy Ag J R | Verfahren zur Stabilisierung eines oralen,fluessigen Arzneimittels auf der Basis von Imipramin und einem Ionenaustauscherharz |
Also Published As
| Publication number | Publication date |
|---|---|
| GB935639A (en) | 1963-09-04 |
| US3138525A (en) | 1964-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH418528A (de) | Verfahren zur Herstellung einer neuen als Arzneimittel zur oralen Verabreichung geeigneten amprotropinhaltigen Zubereitung | |
| AT238716B (de) | Verfahren zur Herstellung von neuen Derivaten des 7-Oxycumarins | |
| AT244317B (de) | Verfahren zur Herstellung von neuen Farnesylesigsäureestern | |
| AT239788B (de) | Verfahren zur Herstellung von neuen β-Carbolin-carbonsäureamid-Derivaten | |
| AT238720B (de) | Verfahren zur Herstellung von neuen 6,11-Dihydro-dibenz(b,e)-thiepin-Derivaten | |
| CH469093A (de) | Verfahren zur Herstellung eines neuen Impfstoffes gegen Panleucopenia | |
| CH418340A (de) | Verfahren zur Herstellung eines neuen Derivats des 1,3-Diazacyclopentens | |
| AT265513B (de) | Verfahren zur Herstellung von neuen Cephalosporinderivaten | |
| AT249885B (de) | Verfahren zur Herstellung eines neuen Hexapeptids | |
| CH379507A (de) | Verfahren zur Herstellung von neuen 10-(1'-Hydroxyalkyl-pyrrolidyl-(3')-methyl)-phenothiazinen | |
| CH383979A (de) | Verfahren zur Herstellung von neuen Iminodibenzylderivaten | |
| AT243273B (de) | Verfahren zur Herstellung von neuen Oxazinderivaten | |
| CH407120A (de) | Verfahren zur Herstellung von neuen Piperidinderivaten | |
| CH426847A (de) | Verfahren zur Herstellung von neuen therapeutisch wirksamen Pyrazolonderivaten | |
| CH386428A (de) | Verfahren zur Herstellung von neuen Iminodibenzylderivaten | |
| AT250360B (de) | Verfahren zur Herstellung von neuen Piperidinderivaten | |
| AT240849B (de) | Verfahren zur Herstellung von neuen 5-Nitrofuran-Derivaten | |
| AT262502B (de) | Verfahren zur Herstellung einer stabilen und pharmazeutisch verwendbaren Insulinlösung | |
| AT250572B (de) | Verfahren zur Herstellung von neuen Heptapeptidderivaten | |
| AT241473B (de) | Verfahren zur Herstellung von neuen 1-Azathiaxanthenderivaten | |
| CH419147A (de) | Verfahren zur Herstellung einer neuen heterocyclischen Verbindung | |
| AT242147B (de) | Verfahren zur Herstellung von neuen 4-Hydroxy-5-halogen-pyrimidinderivaten | |
| AT255661B (de) | Verfahren zur Herstellung von neuen 1-Cyancolchicinderivaten | |
| CH484905A (de) | Verfahren zur Herstellung eines neuen Lokalanästhetikums | |
| CH407118A (de) | Verfahren zur Herstellung eines neuen Piperidinderivates |